(OA-50) Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from the CC-220-MM-001 Trial
Location: Room 701
Abstract Presenter: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
08:10 - 08:20 East Coast USA Time
(OA-46) Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022-05)
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
08:20 - 08:30 East Coast USA Time
(OA-48) Final Analysis of the GEM-BELA-VRd Phase II Trial: Belantamab Mafodotin Plus VRd in Newly Diagnosed Transplant-Eligible Myeloma After 2 Years of Maintenance with Belantamab and Lenalidomide
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
08:30 - 08:40 East Coast USA Time
(OA-47) Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
08:40 - 08:50 East Coast USA Time
(OA-51) Carfilzomib, Lenalidomide, and Dexamethasone (KRd) after Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Analysis of High-Risk Subset in Phase 3 ATLAS Trial
(OA-23) Circulating Tumor Cells for the Staging of Multiple Myeloma: First Results of a European Pooled Analysis of 2432 Patients with Newly Diagnosed Multiple Myeloma and Plasma Cell Leukemia
Location: Room 718
Abstract Presenter: Luca Bertamini, MD (he/him/his) – Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
MRD and Biomarkers
08:20 - 08:30 East Coast USA Time
(OA-25) High Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial
Location: Room 718
Abstract Presenter: Mattia D'Agostino, MD – Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
MRD and Biomarkers
08:30 - 08:40 East Coast USA Time
(OA-22) Comparative Analysis of Four NGS Protocols for Measurable Residual Disease Assessment Testing ctDNA and Bone Marrow Samples in Multiple Myeloma
Location: Room 718
Abstract Presenter: Silvia Armuzzi, MS (she/her/hers) – Department of Medical and Surgical Sciences - University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna
MRD and Biomarkers
08:40 - 08:50 East Coast USA Time
(OA-24) Assessment For Circulating Plasma Cell Enhances R2-ISS in Newly Diagnosed Multiple Myeloma
(OA-45) Cell-Free BCL2 exRNA, but not MYC or MIZ1, Identifies Smouldering Myeloma with a High Risk of Progression among Patients in the Myeloma Related Disease Registry (MRDR)
(OA-58) Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
09:10 - 09:20 East Coast USA Time
(OA-54) Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
Location: Room 701
Abstract Presenter: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
09:20 - 09:30 East Coast USA Time
(OA-57) IVIG and Longer Dosing Intervals Reduce Risk of Infections in Patients with RRMM Treated with Teclistamab
Location: Room 701
Abstract Presenter: Febe Smits, MD – Department of Hematology, Amsterdam UMC, Amsterdam, The Netherlands
Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
09:30 - 09:40 East Coast USA Time
(OA-59) The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7
(OA-60) Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral Treatment
Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
11:10 - 11:20 East Coast USA Time
(OA-52) Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
11:20 - 11:30 East Coast USA Time
(OA-38) A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Mm): Primary Analysis. Amarc 19-02 Belacard Study
(OA-40) A Novel Dual Proteasome and HDAC6 Inhibitor I3MV-8b Potentiates Anti-CD38 Monoclonal Antibody Efficacy in Multiple Myeloma
Location: Room 718
Abstract Presenter: Lanting Liu, MD – State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases;Haihe Laboratory of Cell Ecosystem; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College
Myeloma Novel Drug Targets and agents
11:20 - 11:30 East Coast USA Time
(OA-39) Targeting PHF19 Inhibits Myeloma progression and Increases IMiDs Sensitivity by Epigenetically Regulating MYC and IRF4 Pathway
Location: Room 718
Abstract Presenter: Xiyue Sun, PhD student (she/her/hers) – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Myeloma Novel Drug Targets and agents
11:30 - 11:40 East Coast USA Time
(OA-34) Exploring Molecular Glues to Activate Proteasomes and Develop Shared and Personalized Neoantigen-Based Therapeutics in Multiple Myeloma
Speaker: Nizar J. Bahlis, MD – Arnie Charbonneau Cancer Institute - University of Calgary
12:15 - 12:30 East Coast USA Time
Basic Research
Location: Hall FG
Speaker: Lawrence H. Boise, PhD – Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA, USA
12:30 - 12:45 East Coast USA Time
Clinical Research
Location: Hall FG
Speaker: Marc S. Raab, MD PhD (he/him/his) – Dept. of Medicine V Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
